Kết quả tìm kiếm - Jianqin Shan

Tinh chỉnh kết quả
  1. 1
    Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia

    Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia Bằng Ahmed Aribi, Gautam Borthakur, Farhad Ravandi, Jianqin Shan, Jan Davisson, Jorge E. Cortés, Hagop M. Kantarjian

    Được phát hành 2007
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  2. 2
    Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response

    Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia in Complete Cytogenetic Response Bằng Hagop M. Kantarjian, Jianqin Shan, Daniel M. Jones, Susan O’Brien, Mary Beth Rios, Elias Jabbour, Jorge E. Cortés

    Được phát hành 2009
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  3. 3
    Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy

    Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy Bằng Dushyant Verma, Hagop M. Kantarjian, Jianqin Shan, Susan O’Brien, Zeev Estrov, Guillermo Garcia‐Manero, Charles Koller, Gautam Borthakur, Jorge E. Cortés

    Được phát hành 2010
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  4. 4
    Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response?

    Front-Line Therapy With Second-Generation Tyrosine Kinase Inhibitors in Patients With Early Chronic Phase Chronic Myeloid Leukemia: What Is the Optimal Response? Bằng Elias Jabbour, Hagop M. Kantarjian, Susan O’Brien, Jianqin Shan, Alfonso Quintás‐Cardama, Guillermo Garcia‐Manero, Mary Beth Rios, Jorge E. Cortés

    Được phát hành 2011
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  5. 5
    Chromosomal abnormalities in Philadelphia chromosome–negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase

    Chromosomal abnormalities in Philadelphia chromosome–negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chr... Bằng Elias Jabbour, Hagop M. Kantarjian, Lynne V. Abruzzo, Susan O’Brien, Guillermo Garcia‐Manero, Srđan Verstovšek, Jianqin Shan, Mary Beth Rios, Jorge E. Cortés

    Được phát hành 2007
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  6. 6
    Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy

    Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase recei... Bằng Alfonso Quintás‐Cardama, Hagop M. Kantarjian, Dan Jones, Jianqin Shan, Gautam Borthakur, Deborah A. Thomas, Steven M. Kornblau, Susan O’Brien, Jorge E. Cortés

    Được phát hành 2009
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  7. 7
    Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia

    Results of Dasatinib Therapy in Patients With Early Chronic-Phase Chronic Myeloid Leukemia Bằng Jorge E. Cortés, Dan Jones, Susan O’Brien, Elias Jabbour, Farhad Ravandi, Charles Koller, Gautam Borthakur, Brenda Walker, Weiqiang Zhao, Jianqin Shan, Hagop M. Kantarjian

    Được phát hành 2009
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  8. 8
    Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long‐term outcome of patients with early chronic myeloid leukemia in chronic phase

    Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long‐term outcome of patients with early chronic myeloid leukemia in chronic phase Bằng Yesid Alvarado, Hagop M. Kantarjian, Susan O’Brien, Stefan Faderl, Gautam Borthakur, Jan A. Burger, William G. Wierda, Guillermo Garcia‐Manero, Jianqin Shan, Jorge E. Cortés

    Được phát hành 2009
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  9. 9
    Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia

    Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia Bằng Hagop M. Kantarjian, Susan O’Brien, Jianqin Shan, Xuelin Huang, Guillermo Garcia‐Manero, Stefan Faderl, Farhad Ravandi‐Kashani, Srđan Verstovšek, Mary Beth Rios, Jorge E. Cortés

    Được phát hành 2007
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  10. 10
    Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome

    Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome Bằng Hagop M. Kantarjian, Susan O’Brien, Jianqin Shan, Ahmed Aribi, Guillermo Garcia‐Manero, Elias Jabbour, Farhad Ravandi, Jorge E. Cortés, Jan Davisson, Jean–Pierre J. Issa

    Được phát hành 2006
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  11. 11
    Long‐term follow‐up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome

    Long‐term follow‐up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome Bằng Hagop M. Kantarjian, Miloslav Beran, Jorge E. Cortés, Susan O’Brien, Francis J. Giles, Sherry Pierce, Jianqin Shan, William Plunkett, Michael J. Keating, Elihu H. Estey

    Được phát hành 2006
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  12. 12
    Association of Comorbidities With Overall Survival in Myelodysplastic Syndrome: Development of a Prognostic Model

    Association of Comorbidities With Overall Survival in Myelodysplastic Syndrome: Development of a Prognostic Model Bằng Kiran Naqvi, Guillermo Garcia‐Manero, Sagar Sardesai, Jeong Hoon Oh, Carlos E. Vigil, Sherry Pierce, Xiudong Lei, Jianqin Shan, Hagop M. Kantarjian, María E. Suärez-Almazor

    Được phát hành 2011
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  13. 13
    Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase

    Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase Bằng Jorge E. Cortés, Dan Jones, Susan O’Brien, Elias Jabbour, Marina Konopleva, Alessandra Ferrajoli, Tapan M. Kadia, Gautam Borthakur, Denise Stigliano, Jianqin Shan, Hagop M. Kantarjian

    Được phát hành 2009
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  14. 14
    Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

    Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia Bằng Hagop M. Kantarjian, Moshe Talpaz, Susan O’Brien, Francis J. Giles, Guillermo Garcia‐Manero, Stefan Faderl, Deborah A. Thomas, Jianqin Shan, Mary Beth Rios, Jorge E. Cortés

    Được phát hành 2002
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  15. 15
    Outcome of patients with Philadelphia chromosome‐positive chronic myelogenous leukemia post‐imatinib mesylate failure

    Outcome of patients with Philadelphia chromosome‐positive chronic myelogenous leukemia post‐imatinib mesylate failure Bằng Hagop M. Kantarjian, Susan O’Brien, Moshe Talpaz, Gautam Borthakur, Farhad Ravandi, Stefan Faderl, Srđan Verstovšek, Mary Beth Rios, Jianqin Shan, Francis J. Giles, Jorge E. Cortés

    Được phát hành 2007
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  16. 16
    Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high‐risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities

    Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high‐risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities Bằng Farhad Ravandi, Jean–Pierre J. Issa, Guillermo Garcia‐Manero, Susan O’Brien, Sherry Pierce, Jianqin Shan, Gautam Borthakur, Srđan Verstovšek, Stefan Faderl, Jorge E. Cortés, Hagop M. Kantarjian

    Được phát hành 2009
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  17. 17
    Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome

    Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome Bằng Hagop M. Kantarjian, Susan O’Brien, Xuelin Huang, Guillermo Garcia‐Manero, Farhad Ravandi, Jorge E. Cortés, Jianqin Shan, Jan Davisson, Carlos E. Bueso‐Ramos, Jean–Pierre J. Issa

    Được phát hành 2007
    lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  18. 18
    Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:

    Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome: Bằng Hagop M. Kantarjian, Susan O’Brien, Jorge E. Cortés, Francis J. Giles, Stefan Faderl, Elias Jabbour, Guillermo Garcia‐Manero, William G. Wierda, Sherry Pierce, Jianqin Shan, Elihu H. Estey

    Được phát hành 2006
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  19. 19
    Survival benefit with imatinib mesylate versus interferon-α–based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia

    Survival benefit with imatinib mesylate versus interferon-α–based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia Bằng Hagop M. Kantarjian, Moshe Talpaz, Susan O’Brien, Daniel M. Jones, Francis J. Giles, Guillermo Garcia‐Manero, Stefan Faderl, Farhad Ravandi, Mary Beth Rios, Jianqin Shan, Jorge E. Cortés

    Được phát hành 2006
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:
  20. 20
    Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy

    Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy Bằng Farhad Ravandi, Jorge E. Cortés, Stefan Faderl, Susan O’Brien, Guillermo Garcia‐Manero, Srđan Verstovšek, Fabio P S Santos, Jianqin Shan, Mark Brandt, Marcos de Lima, Sherry Pierce, Hagop M. Kantarjian

    Được phát hành 2010
    lấy văn bản lấy văn bản
    Artigo
    Lưu vào danh sách
    Đã lưu trong:

Công cụ tìm kiếm: